{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:56:32Z","timestamp":1763754992229,"version":"3.45.0"},"reference-count":19,"publisher":"Oncology Nursing Society (ONS)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJON"],"published-print":{"date-parts":[[2020,6,1]]},"DOI":"10.1188\/20.cjon.240-243","type":"journal-article","created":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T10:42:30Z","timestamp":1590144150000},"page":"240-243","source":"Crossref","is-referenced-by-count":6,"title":["Adrenal Insufficiency: Immune Checkpoint Inhibitors and Immune-Related Adverse Event Management"],"prefix":"10.1188","volume":"24","author":[{"given":"Kiera","family":"Hobbs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Yackzan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2020,6,1]]},"reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Bancos, I., Hahner, S., Tomlinson, J., & Arit, W. (2015). Diagnosis and management of adrenal insufficiency. Lancet Diabetes and Endocrinology, 3(3), 216\u2013226. https:\/\/doi.org\/10.1016\/S2213-8587(14)70142-1","DOI":"10.1016\/S2213-8587(14)70142-1"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Barroso-Sousa, R., Ott, P.A., Hodi, F.S., Kaiser, U.B., Tolaney, S.M., & Min, L. (2018). Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management. Cancer, 124(6), 1111\u20131124. https:\/\/doi.org\/10.1002\/cncr.31200","DOI":"10.1002\/cncr.31200"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Barthel, A., Benker, G., Berens, K., Diederich, S., Manfras, B., Gruber, M., . . . Bornstein, S.R. (2018). An update on Addison\u2019s disease. Experimental and Clinical Endocrinology and Diabetes, 127(02\/03), 165\u2013170. https:\/\/doi.org\/10.1055\/a-0804-2715","DOI":"10.1055\/a-0804-2715"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Bornstein, S.R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G.D., . . . Torpy, D.J. (2016). Diagnosis and treatment of primary adrenal insufficiency: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism, 101(2), 364\u2013389. https:\/\/doi.org\/10.1210\/jc.2015-1710","DOI":"10.1210\/jc.2015-1710"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Byrd, J.B., Turcu, A.F., & Auchus, R.J. (2018). Primary aldosteronism: Practical approach to diagnosis and management. Circulation, 138(8), 823\u2013835. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.033597","DOI":"10.1161\/CIRCULATIONAHA.118.033597"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Chang, L.-S., Barroso-Sousa, R., Tolaney, S.M., Hodi, F.S., Kaiser, U.B., & Min, L. (2019). Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocrine Reviews, 40(1), 17\u201365. https:\/\/doi.org\/10.1210\/er.2018-00006","DOI":"10.1210\/er.2018-00006"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Cole, S. (2018). Evaluation and treatment of adrenal dysfunction in the primary care environment. Nursing Clinics of North America, 53(3), 385\u2013394. https:\/\/doi.org\/10.1016\/j.cnur.2018.04.007","DOI":"10.1016\/j.cnur.2018.04.007"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Cukier, P., Santini, F.C., Scaranti, M., & Hoff, A.O. (2017). Endocrine side effects of cancer immunotherapy. Endocrine-Related Cancer, 24(12), T331\u2013T347. https:\/\/doi.org\/10.1530\/ERC-17-0358","DOI":"10.1530\/ERC-17-0358"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Debono, M., Ghobadi, C., Rostami-Hodjegan, A., Huatan, H., Campbell, M.J., Newell-Price, J., . . . Ross, R.J. (2009). Modified-release hydrocortisone to provide circadian cortisol profiles. Journal of Clinical Endocrinology and Metabolism, 94(5), 1548\u20131554. https:\/\/doi.org\/10.1210\/jc.2008-2380","DOI":"10.1210\/jc.2008-2380"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Gordon, R., Kasler, M.K., Stasi, K., Shames, Y., Errante, M., Ciccolini, K., . . . Fischer-Cartlidge, E. (2017). Checkpoint inhibitors: Common immune-related adverse events and their management. Clinical Journal of Oncology Nursing, 21(2), 45\u201352. https:\/\/doi.org\/10.1188\/17.CJON.S2.45-52","DOI":"10.1188\/17.CJON.S2.45-52"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Guo, L., Zhang, H., & Chen, B. (2017). Nivolumab as programmed death-1 (PD-1) inhibitor for targeted immunotherapy in tumor. Journal of Cancer, 8(3), 410\u2013416. https:\/\/doi.org\/10.7150\/jca.17144","DOI":"10.7150\/jca.17144"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Kumar, V., Chaudhary, N., Garg, M., Floudas, C.S., Soni, P., & Chandra, A.B. (2017). Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Frontiers in Pharmacology, 8, 49. https:\/\/doi.org\/10.3389\/fphar.2017.00049","DOI":"10.3389\/fphar.2017.00049"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C.D., . . . Wolchok, J.D. (2019). Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. New England Journal of Medicine, 381(16), 1535\u20131546. https:\/\/doi.org\/10.1056\/NEJMoa1910836","DOI":"10.1056\/NEJMoa1910836"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Makin, V., Nowacki, A.S., & Colbert, C.Y. (2019). A pilot assessment of primary care providers\u2019 knowledge of adrenal insufficiency diagnosis and management. Journal of Primary Care and Community Health, 10, 2150132719862163. https:\/\/doi.org\/10.1177\/2150132719862163","DOI":"10.1177\/2150132719862163"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Nagasaka, M., Abdallah, N., Samantray, J., & Sukari, A. (2018). Is this really just \u201cfatigue\u201d? A case series of immune related central adrenal insufficiency secondary to immune checkpoint inhibitors. Clinical Case Reports, 6(7), 1278\u20131281. https:\/\/doi.org\/10.1002\/ccr3.1567","DOI":"10.1002\/ccr3.1567"},{"key":"16","unstructured":"Nieman, L.K. (2019). Patient education: Adrenal insufficiency (Addison\u2019s disease) (Beyond the Basics). In K.A. Martin (Ed.), UpToDate. Retrieved February 1, 2020, from https:\/\/www.uptodate.com\/contents\/adrenal-insufficiency-addisons-disease..."},{"key":"17","doi-asserted-by":"crossref","unstructured":"Ospina, N.S., Nofal, A.A., Bancos, I., Javed, A., Benkhadra, K., Kapoor, E., . . . Murad, M.H. (2016). ACTH stimulation tests for the diagnosis of adrenal insufficiency: Systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism, 101(2), 427\u2013434. https:\/\/doi.org\/10.1210\/jc.2015-1700","DOI":"10.1210\/jc.2015-1700"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Pazderska, A., & Pearce, S.H.S. (2017). Adrenal insufficiency\u2014Recognition and management. Clinical Medicine, 17(3), 258\u2013262. https:\/\/doi.org\/10.7861\/clinmedicine.17-3-258","DOI":"10.7861\/clinmedicine.17-3-258"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Wood, L.S. (2019). Immune-related adverse events from immunotherapy: Incorporating care step pathways to improve management across tumor types. Journal of the Advanced Practitioner in Oncology, 10(Suppl. 1), 47\u201362. https:\/\/doi.org\/10.6004\/jadpro.2019.10.2.13","DOI":"10.6004\/jadpro.2019.10.2.13"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/cjon.ons.org\/cjon\/24\/3\/adrenal-insufficiency-immune-checkpoint-inhibitors-and-immune-related-adverse-event","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:50:18Z","timestamp":1763754618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/24\/3\/adrenal-insufficiency-immune-checkpoint-inhibitors-and-immune"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,1]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6,1]]}},"URL":"https:\/\/doi.org\/10.1188\/20.cjon.240-243","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"type":"print","value":"1092-1095"},{"type":"electronic","value":"1538-067X"}],"subject":[],"published":{"date-parts":[[2020,6,1]]}}}